MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)

Phase 3

MYLAN (VTRS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Asthma

TEVAasthma inhalers

PHM.MCLevalbuterol

Phase 3

ALPMYTacrolimus Inhalation Aerosol

Drug Information

Target Indication

Asthma

Clinical Trial

NCT02245672

Last updated: 8/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VTRS

MYLAN

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MYL-1601D ProductPhase 3

Diabetes Mellitus, Type 1

venlafaxine ER 75 mg/day (fixed dose)Phase 3

Major Depressive Disorder

LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATIONPhase 3

Glaucoma, Primary Open Angle (POAG)

RevefenacinPhase 3

Chronic Obstructive Pulmonary Disease, COPD

Amlodipine/atorvastatin single pillPhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts